Equity Overview
Price & Market Data
Price: $23.70
Daily Change: -$0.50 / 2.11%
Daily Range: $23.36 - $24.44
Market Cap: $599,588,736
Daily Volume: 147,242
Performance Metrics
1 Week: -2.67%
1 Month: 9.12%
3 Months: 48.87%
6 Months: 24.74%
1 Year: 24.74%
YTD: 6.47%
Details
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.